These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 28585707)

  • 61. A global approach to psoriatic patients through PASI score and Skindex-29.
    Prignano F; Ruffo G; Ricceri F; Pescitelli L; Lotti T
    G Ital Dermatol Venereol; 2011 Feb; 146(1):47-52. PubMed ID: 21317856
    [TBL] [Abstract][Full Text] [Related]  

  • 62. A phase IIIb, multicentre, randomized, double-blind, vehicle-controlled study of the efficacy and safety of adalimumab with and without calcipotriol/betamethasone topical treatment in patients with moderate to severe psoriasis: the BELIEVE study.
    Thaçi D; Ortonne JP; Chimenti S; Ghislain PD; Arenberger P; Kragballe K; Saurat JH; Khemis A; Sprøgel P; Esslinger HU; Unnebrink K; Kupper H
    Br J Dermatol; 2010 Aug; 163(2):402-11. PubMed ID: 20377585
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Gene expression profiles normalized in psoriatic skin by treatment with brodalumab, a human anti-IL-17 receptor monoclonal antibody.
    Russell CB; Rand H; Bigler J; Kerkof K; Timour M; Bautista E; Krueger JG; Salinger DH; Welcher AA; Martin DA
    J Immunol; 2014 Apr; 192(8):3828-36. PubMed ID: 24646743
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Use of brodalumab for the treatment of psoriasis and psoriatic arthritis.
    Kivelevitch DN; Menter A
    Immunotherapy; 2015; 7(4):323-33. PubMed ID: 25917624
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Rebound of psoriasis after efalizumab discontinuation, despite being on high-dose cyclosporine.
    Maskatia ZK; Koo J
    J Drugs Dermatol; 2007 Sep; 6(9):941-4. PubMed ID: 17941368
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial.
    Gordon KB; Papp KA; Hamilton TK; Walicke PA; Dummer W; Li N; Bresnahan BW; Menter A;
    JAMA; 2003 Dec; 290(23):3073-80. PubMed ID: 14679270
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Approaches to discontinuing efalizumab: an open-label study of therapies for managing inflammatory recurrence.
    Papp KA; Toth D; Rosoph L
    BMC Dermatol; 2006 Oct; 6():9. PubMed ID: 17067371
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Treatment with brodalumab is not associated with improved sleep problems in real-life patients with plaque psoriasis: Results of the ProLOGUE study.
    Mizutani Y; Kanai Y; Murotani K; Honma M; Higashiyama M; Kobayashi S; Nomura T; Seishima M; Imafuku S
    J Dermatol; 2023 Mar; 50(3):319-326. PubMed ID: 36342070
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Brodalumab (Siliq
    Gupta AK; Versteeg SV; Abramovits W; Vincent KD
    Skinmed; 2017; 15(4):281-285. PubMed ID: 28859739
    [No Abstract]   [Full Text] [Related]  

  • 70. Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics.
    Papoutsaki M; Chimenti MS; Costanzo A; Talamonti M; Zangrilli A; Giunta A; Bianchi L; Chimenti S
    J Am Acad Dermatol; 2007 Aug; 57(2):269-75. PubMed ID: 17574299
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Life-threatening pustular and erythrodermic psoriasis responding to infliximab.
    Lewis TG; Tuchinda C; Lim HW; Wong HK
    J Drugs Dermatol; 2006 Jun; 5(6):546-8. PubMed ID: 16774108
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Adalimumab for the treatment of psoriasis in real life: a retrospective cohort of 119 patients at a single Spanish centre.
    López-Ferrer A; Vilarrasa E; Gich IJ; Puig L
    Br J Dermatol; 2013 Nov; 169(5):1141-7. PubMed ID: 23909993
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Efficacy and safety results from a phase III, randomized controlled trial comparing the safety and efficacy of briakinumab with etanercept and placebo in patients with moderate to severe chronic plaque psoriasis.
    Strober BE; Crowley JJ; Yamauchi PS; Olds M; Williams DA
    Br J Dermatol; 2011 Sep; 165(3):661-8. PubMed ID: 21574984
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Adalimumab retreatment successfully restores clinical response and health-related quality of life in patients with moderate to severe psoriasis who undergo therapy interruption.
    Gordon KB; Gottlieb AB; Langely RG; van de Kerkhof P; Belasco KT; Sundaram M; Okun M; Serra L
    J Eur Acad Dermatol Venereol; 2015 Apr; 29(4):767-76. PubMed ID: 25284275
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Efficacy and safety of biologics in erythrodermic psoriasis: a multicentre, retrospective study.
    Viguier M; Pagès C; Aubin F; Delaporte E; Descamps V; Lok C; Beylot-Barry M; Séneschal J; Dubertret L; Morand JJ; Dréno B; Bachelez H;
    Br J Dermatol; 2012 Aug; 167(2):417-23. PubMed ID: 22413927
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Successful treatment of palmoplantar pustular psoriasis with brodalumab.
    Nakao M; Asano Y; Kamata M; Yoshizaki A; Sato S
    Eur J Dermatol; 2018 Aug; 28(4):538-539. PubMed ID: 30129522
    [No Abstract]   [Full Text] [Related]  

  • 77. Transitioning Between Brodalumab and Secukinumab in Moderate to Severe Psoriasis: An Early Look.
    Vender RB
    J Drugs Dermatol; 2016 Aug; 15(8):941-3. PubMed ID: 27537993
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Effect of infliximab on health-related quality of life and disease activity by body region in patients with moderate-to-severe psoriasis and inadequate response to etanercept: results from the PSUNRISE trial.
    Kalb RE; Blauvelt A; Sofen HL; Chevrier M; Amato D; Calabro S; Wang J; Schenkel B; Gottlieb AB
    J Drugs Dermatol; 2013 Aug; 12(8):874-80. PubMed ID: 23986160
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Patients with moderate to severe plaque psoriasis: one year after the European Medicines Agency recommendation of efalizumab suspension.
    Talamonti M; Teoli M; Botti E; Spallone G; Chimenti S; Costanzo A
    Dermatology; 2011; 222(3):250-5. PubMed ID: 21494026
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Depression and suicidality in psoriasis and clinical studies of brodalumab: a narrative review.
    Koo J; Ho RS; Thibodeaux Q
    Cutis; 2019 Dec; 104(6):361-365. PubMed ID: 31939925
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.